ReviewFrontiers in public health2014
Vector saliva in vaccines for visceral leishmaniasis: a brief encounter of high consequence?
Review in Frontiers in public health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Neglected tropical disease (NTD) diagnostics: current development and operations to advance control.Pathogens and global health · 2024Review
- Some Good and Some Bad: Sand Fly Salivary Proteins in the Control of Leishmaniasis and in Autoimmunity.Frontiers in cellular and infection microbiology · 2022Review
- Article
- Precision Medicine in Control of Visceral Leishmaniasis Caused byFrontiers in cellular and infection microbiology · 2021Review
- Cytokines and splenic remodelling duringCytokine: X · 2020Article
- Engineering a vector-based pan-Leishmania vaccine for humans: proof of principle.Scientific reports · 2020Article
- Functional and structural similarities of D7 proteins in the independently-evolved salivary secretions of sand flies and mosquitoes.Scientific reports · 2019Article
- Immunization of Experimental Dogs With Salivary Proteins FromFrontiers in immunology · 2018Article
- Epidemiological consequences of immune sensitisation by pre-exposure to vector saliva.PLoS neglected tropical diseases · 2017Article
- Anopheline salivary protein genes and gene families: an evolutionary overview after the whole genome sequence of sixteen Anopheles species.BMC genomics · 2017Article
- Eliminating the Neglected Tropical Diseases: Translational Science and New Technologies.PLoS neglected tropical diseases · 2016Review
- Post-Genomics and Vaccine Improvement for Leishmania.Frontiers in microbiology · 2016Review
- Arthropod Vectors and Disease Transmission: Translational Aspects.PLoS neglected tropical diseases · 2015Article
- Recent advances in phlebotomine sand fly research related to leishmaniasis control.Parasites & vectors · 2015Article
- Infectiousness of Sylvatic and Synanthropic Small Rodents Implicates a Multi-host Reservoir of Leishmania (Viannia) braziliensis.PLoS neglected tropical diseases · 2015Article
- Targeted Immunology for Prevention and Cure of VL.Frontiers in immunology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Visceral leishmaniasis (VL) is a vector-borne disease transmitted by phlebotomine sand flies and remains the most serious form of the disease with no available human vaccine. Repeatedly, studies have demonstrated the immunogenicity and protective efficacy of a number of sand fly salivary proteins against cutaneous and visceral leishmaniasis. All Leishmania species including agents of VL are co-deposited into the skin together with vector saliva. Generally, the immune response to a protective salivary protein in vaccinated animals is rapid and possibly acts on the parasites soon after delivery into the skin by the bite of an infective sand fly. This is followed by the development of a stronger Leishmania-specific immunity in saliva-vaccinated animals compared to controls. Considering that several of the most efficacious protective molecules were identified from a proven vector of VL, we put forward the notion that a combination vaccine that includes a Leishmania antigen and a vector salivary protein has the potential to improve vaccine efficacy by targeting the parasite at it most vulnerable stage just after transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.